ROCHESTER, N.Y., May 21 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-based biomarker solutions, announced today that it released its next generation 2.0 software platform for the use of imaging in clinical trials. This industry-leading platform draws upon seven years of experience in imaging to deliver operational efficiencies and enhanced reporting in order to expedite customers' clinical trial process.
The new platform provides FDA required 21 CFR Part 11 compliant tools for managing international imaging sites. These latest capabilities give the VirtualScopics a scalable global reach that is essential to conducting later stage clinical trials. The software platform includes a new image analysis automation system, improved traceability, enhanced tools for data management, in addition to real-time detailed reports for VirtualScopics' customers.
"We are excited about the release of the 2.0 platform as it not only makes us more efficient in later stage clinical trials but also incorporates many features that our customers have requested relative to reporting and data mining. These enhancements provide our customers access to critical information earlier in the process, to further accelerate drug development," said Jeff Markin, president and chief executive officer of VirtualScopics, Inc. "This software release provides a solid platform for additional planned releases that will enhance our ability to provide real-time information to our customers on a global basis."
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Tim Ryan Bagatelle-Black Public Relations Trout Group Investor Relations 661/263-1842 (646) 378-2924 tracy@bagatelleblack.comtryan@troutgroup.com
VirtualScopics, Inc.CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations,+1-661-263-1842, or tracy@bagatelleblack.com; or Tim Ryan of Trout GroupInvestor Relations, +1-646-378-2924, or tryan@troutgroup.com, forVirtualScopics, Inc.
Web site: http://www.virtualscopics.com/
